<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376103</url>
  </required_header>
  <id_info>
    <org_study_id>MHIRB 2006-032</org_study_id>
    <nct_id>NCT00376103</nct_id>
  </id_info>
  <brief_title>Radiation Boost for Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase I/II Trial of Maximal Resection, Local Radiation Boost With Concomitant Temozolomide, Followed by External Radiation Therapy With Concomitant Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine treatment related toxicity, tumor response,&#xD;
      progression-free survival and quality of life of newly diagnosed Glioblastoma Multiforme&#xD;
      (GBM) patients undergoing a combination of surgical resection, brachytherapy and external&#xD;
      beam radiation with concomitant temozolomide, followed by adjuvant temozolomide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is multi-centered and non-randomized. Patients with newly diagnosed GBM&#xD;
      undergoing initial surgical resection will be candidates for this study. Eligible patients&#xD;
      will undergo surgical resection within 30 days of diagnosis.&#xD;
&#xD;
      Newly diagnosed patients with presumed diagnosis of GBM will undergo surgery for maximal&#xD;
      resection. After frozen section diagnosis of GBM is confirmed, the GliaSite® will be placed&#xD;
      into the tumor cavity.&#xD;
&#xD;
      After the patient recovers from surgery, radiation therapy (60 Gy to 1 cm) is delivered via&#xD;
      the GliaSite®. Radiation therapy with the GliaSite® will be initiated within 21 days after&#xD;
      surgery. Concomitant temozolomide (75 mg/m2/d) is started 2 days prior to radiation therapy&#xD;
      with the GliaSite® and continued for a total of 7 days.&#xD;
&#xD;
      Within 21 days following radiation therapy with the GliaSite®, external beam radiation&#xD;
      therapy (60 Gy in 30 fractions) will be initiated. Concomitant temozolomide (75 mg/m2/d) will&#xD;
      start on day 1 of external beam radiation therapy and continue through the external beam&#xD;
      radiation therapy interval, ending with the last day of radiation.&#xD;
&#xD;
      Four weeks (+/- 2 days) after completion of external beam radiation therapy, temozolomide&#xD;
      (150 mg/m2/d) for 5 days every 28 days will be initiated for one cycle.&#xD;
&#xD;
      At the start of cycle 2, the dose will be escalated to 200 mg/m2/d, if the CTC&#xD;
      non-hematological toxicity for cycle 1 is Grade &lt; 2 (except for alopecia, nausea and&#xD;
      vomiting).&#xD;
&#xD;
      This will continue for up to a total of 12 cycles, unless disease progression or severe&#xD;
      myelosuppression is noted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of funding from sponsor&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related toxicity.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 month, 1 year and overall survival.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor progression.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>75 mg/m2/day</description>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>60 Gy to 1 cm</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>60 Gy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, unifocal, unilateral, supratentorial lesion seen on MRI and&#xD;
             suspicious for Glioblastoma Multiforme&#xD;
&#xD;
          -  Subject must be a candidate for surgical resection of the tumor mass with feasible&#xD;
             gross total resection&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Subject must be an appropriate candidate to receive brachytherapy and temozolomide per&#xD;
             the GliaSite RTS and temozolomide IFU&#xD;
&#xD;
          -  The tumor must be histopathologically confirmed by intra-operative frozen section and&#xD;
             by final pathology&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) =&gt; 70&#xD;
&#xD;
          -  Negative pregnancy test if a female of childbearing age and not surgically sterilized&#xD;
&#xD;
          -  Male or female subject agrees to use acceptable birth control methods while receiving&#xD;
             treatment (if not surgically sterile)&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate laboratory results: ANC =&gt; 1.5 x 109/L. Platelets =&gt; 100 x 109/L&#xD;
&#xD;
          -  Subject or legal representative must provide informed consent and HIPAA authorization&#xD;
             prior to surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of temozolomide&#xD;
&#xD;
          -  Presence or history of severe hepatic or renal impairment&#xD;
&#xD;
          -  Subject cannot tolerate temozolomide therapy due to NPO status or intractable nausea&#xD;
             and vomiting&#xD;
&#xD;
          -  Subject with prior intracranial malignancy&#xD;
&#xD;
          -  Major medical illness or psychiatric impairments that in the investigators opinion&#xD;
             will prevent administration or completion of the protocol therapy&#xD;
&#xD;
          -  Subject has pacemaker or other MRI non-compatible metal in the body&#xD;
&#xD;
          -  Previous radiation to the head/neck or brain&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patient has allergy to iodine and/or dacarbazine&#xD;
&#xD;
          -  Creatinine &gt; 1.5x upper limits of normal (ULN), AST &gt; 3x ULN&#xD;
&#xD;
          -  Chemotherapy within the last 6 months&#xD;
&#xD;
          -  Residual tumor &gt;1 cm (in a single dimension) on baseline MRI scan (T1 post-gadolinium&#xD;
             images)&#xD;
&#xD;
          -  Balloon surface within 1 cm of critical structure (brain stem, midbrain, optic chiasm)&#xD;
             on baseline MRI scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen K Sills, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Allen Sills, MD</name_title>
    <organization>Methodist Healthcare</organization>
  </responsible_party>
  <keyword>Brain Tumor</keyword>
  <keyword>GBM</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

